Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study.
Diabetes Res Clin Pract
; 143: 398-408, 2018 Sep.
Article
em En
| MEDLINE
| ID: mdl-29807100
ABSTRACT
AIM:
To assess the effect of metformin on cancer incidence in type 2 diabetes (T2DM), considering possible interactions with other glucose-lowering drugs and diabetes duration.METHODS:
Study cohort included diabetes patients aged 20-84 on December 2009, still alive and resident in Reggio Emilia province as of December 2011. Drug exposure was assessed for 2009-2011; subjects taking metformin continuously, with or without other hypoglycaemic drugs, were compared to subjects on diet-only therapy. The cohort was followed up from 2012 to 2014 through the cancer registry. Age- and sex-adjusted incidence rate ratios (IRRs) were computed using Poisson regression models for all sites, lung, breast, liver, colorectal, prostate and pancreatic cancer.RESULTS:
The cohort includes 17,026 people with T2DM, 7460 taking metformin. 887 cancers occurred during follow-up, 348 among metformin users. Cancer risk was similar in T2DM patients using metformin and those on diet-only. The risk for prostate (IRRâ¯=â¯0.65; 95%CI0.36; 1.17), liver (IRRâ¯=â¯0.82; 95%CI0.36; 1.85) and breast (IRRâ¯=â¯0.77; 95%CI0.43; 1.40) cancers only was slightly reduced; for lung (IRRâ¯=â¯1.52; 95%CI0.92; 2.50), pancreas (IRRâ¯=â¯1.51; 95%CI0.593.89) and colon-rectum (IRRâ¯=â¯1.71; 95%CI0.94; 3.08) the risk was slightly increased.CONCLUSIONS:
There is no evidence of antitumor effect of metformin. A possible decrease only for breast, liver and prostate cancer, is compatible with random fluctuations.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Glucose
/
Hipoglicemiantes
/
Metformina
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article